The development and innovation in the sickle cell disease treatment are encouraging the growth of the sickle cell disease treatment market. For instance, stem cell transplantation is the only potential treatment to cure sickle cell disease treatment. In this treatment, the old stem cell is replaced with the healthy stem cell in bone marrow donated by a matching donor. Bone marrow is the source of new red blood cells, by the transplantation of stem cell the new flexible and round-shaped healthy red blood cells are produced in order to cure the sickle cell disease treatment.
Various medications are approved in order to treat and cure sickle cell disease treatment which is creating enormous opportunities for the sickle cell disease treatment market. For instance, in November 2019, the US FDA approved the Oxybryta (voxelotor) a therapeutic treatment for the treatment of sickle cell disease which is developed by Global Blood Therapeutics. The therapy is developed with the aim to provide prevention from the sticking of hemoglobin in order to smooth the flow of red blood cells in blood vessels to the organs maintaining the flexible shape of the red blood cell.
Browse the full report description of "Sickle Cell Disease Treatment Market Size, Share & Trends Analysis Report, by Type (Medication (Hydroxyurea, L-Glutamine Oral Powder, Crizanlizumab, Voxelotor, Pain-relieving Medication, and others), Blood Transfusions and Bone-Marrow Transplant), by Disease Type (Sickle Cell Anemia, Sickle Hemoglobin C Disease, Sickle Beta-Thalassemia, and Sickle Beta-Zero Thalassemia), and Forecast 2019-2025" at https://www.omrglobal.com/industry-reports/sickle-cell-disease-treatment-market
In November 2019, Novartis AG granted the approval of Adakveo (Crizanluzumab) by the FDA. Adakveo has an antibody that is used to block one of the proteins in the endothelial cells of the blood vessels. This antibody prevents the protein from binding the sickle cells which in turn used to reduce the pain associated with the sickle cell because of blockage in the red blood cells. The major symptom of sickle cell disease is the pain associated with sickle cell and many pain-relieving medications are prescribed in order to cure the acute pain in the patients.
In November 2017, Micelle Bio Pharma, Inc. granted the approval of sickle cell disease treatment Altemia and found many successful results in the reduction of vaso-occlusive crises (VOCs). Altemia is a drug containing a mixture of lipids formulated using advanced lipid technology (ALT) and is primarily designed for the treatment of sickle cell diseases.The drug has the ability to increase the fluidity of red blood cells and treatment of disease by reducing blood cell adhesion, blood cell hemolysis and inflammation.
A new CRISPER (Clustered regularly inter spaced short palindromic repeats) technology is used to replace the stem cell in order to produce a high level of fetal hemoglobin and replacing it with the damaged hemoglobin in the red blood cell. Therefore the emerging developments in the treatment options and drugs will be anticipated to boost the sickle cell disease market.
Sickle Cell Disease Treatment Market Segmentation
By Drug Type
By Disease
Sickle Cell Disease Treatment Market – Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/sickle-cell-disease-treatment-market